A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
Nature Communications·
- DOI
- 10.1038/s41467-020-17892-0
- PMID
- —
- PMCID
- —
- OpenAlex
- W3048799641
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
The described platform is proposed as a scalable tool to screen populations for antibody protection, which the authors frame as relevant to safely reopening communities.
Structured evidence summary
Research question
The study addresses the need for a rapid, high-throughput assay to measure SARS-CoV-2 neutralizing antibodies to support serodiagnosis, convalescent plasma therapy, and vaccine evaluation.
Study design
The work describes the development and validation of a fluorescence-based SARS-CoV-2 neutralization assay, with comparison to the plaque reduction neutralization test as the reference standard and testing against non-COVID specimens for specificity.
Population and setting
Evaluation was performed using specimens from COVID-19 patients and a panel of specimens from individuals with other viral, bacterial, or parasitic infections, as described in the abstract.
Main findings
The fluorescence-based neutralization assay detected SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and showed results comparable to the plaque reduction neutralization assay. The assay did not cross-react with specimens from other viral, bacterial, or parasitic infections.
Public-health relevance
The described platform is proposed as a scalable tool to screen populations for antibody protection, which the authors frame as relevant to safely reopening communities.
Important limitations
The abstract does not state explicit limitations; the summary is limited to the supplied single-article abstract and metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
This article relates to the discoverability of COVID-19 serological and vaccine evaluation methods; no connection to a live surveillance signal is made from this single article.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.